electroCore Provides Update on 510(k) Submission Seeking Expanded Indication for gammaCore™
electroCore, Inc. (ECOR)
Last electrocore, inc. earnings: 3/23 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
BASKING RIDGE, N.J., Sept. 25, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR, or the “Company”), a commercial-stage bioelectronic medicine company, today announced that the U.S. Food and Drug Administration (“FDA”) has requested more information and analysis of the clinical data included in the Company’s premarket notification, or “510(k)” submission, seeking an expanded indication for the use of gammaCore™ (non-invasive vagus nerve stimulator). Although the Company has 180 days to respond to FDA’s request, the Company expects to meet with the FDA in the fourth quarter to discuss the information request. gammaCore™ is currently FDA-cleared for the treatment of pain associated with episodic cluster headache and migraine headache, and adjunctive use for the prevention of cluster headache. The data submitted in the 510(k) include the results of the Premium 1 study, a randomized, double-blind, sham-controlled trial of gammaCore™ recently published in the journal Cephalalg
Show less
Read more
Impact Snapshot
Event Time:
ECOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ECOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ECOR alerts
High impacting electroCore, Inc. news events
Weekly update
A roundup of the hottest topics
ECOR
News
- electroCore Announces the Launch of Truvaga Plus® for General WellnessGlobeNewswire
- electroCore Expands Intellectual Property PortfolioGlobeNewswire
- electroCore, Inc. (NASDAQ: ECOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- ElectroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- electroCore Announces Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire
ECOR
Earnings
- 3/13/24 - Miss
ECOR
Analyst Actions
- 3/18/24 - HC Wainwright
ECOR
Sec Filings
- 3/14/24 - Form S-8
- 3/13/24 - Form 10-K
- 3/13/24 - Form 8-K
- ECOR's page on the SEC website